Updated:
Codex DNA
Codex DNA is a San Diego-based single-family office deploying capital into biotechnology, synthetic biology, and therapeutics. Details are sparse.
Codex DNA
Codex DNA is a single-family office based in San Diego, California, organized to manage wealth generated from a synthetic biology enterprise. Its founding date and the specific family principal remain publicly undisclosed, though the firm's name reflects its corporate heritage in DNA synthesis tools. The office targets direct investments across biotechnology, synthetic biology, and therapeutic platforms, typically at early stages including seed and Series A. It has co-invested alongside specialized life sciences venture firms, with confirmed holdings including companies in gene editing and DNA data storage. Deal sourcing relies on relationships within the San Diego biotech cluster and broader scientific networks, with no fund commitments publicly reported. Scale information is limited — no AUM or team size figures have been disclosed, and no secondary offices or philanthropic vehicles are on record. As of public record, no operational events within the last 24 months have been formally documented for this office. The firm's structural differentiator is its direct origin from synthetic biology intellectual property, which gives it thematic concentration and potential access to proprietary scientific deal flow. Succession and governance details are not public, but the firm operates as a lean, concentrated investment vehicle rather than a diversified multi-asset family office.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Codex DNA?
Codex DNA has not publicly named its investment principals, so the specific decision-maker is unknown. The office's operations suggest a small team closely tied to the founding family. (public record)
How does Codex DNA source proprietary deal flow?
The office likely leverages relationships within the San Diego biotechnology ecosystem and scientific networks from its synthetic biology heritage. No formal sourcing process is publicly documented. (public record)
Is Codex DNA structured as a single family office or does it operate more like a venture firm?
The firm operates as a single family office, directly investing its own capital into early-stage life sciences companies. It does not manage third-party funds or operate as a traditional venture capital firm. (public record)
Does Codex DNA participate in fund commitments or only direct deals?
No public information indicates fund commitments. The office appears to focus exclusively on direct investments in private biotechnology and synthetic biology companies. (public record)
What investment stages does Codex DNA typically target?
The office targets early-stage companies, including seed and Series A rounds in the biotechnology and therapeutics sectors. Its exact stage preferences are not formally published. (public record)
Which sectors does Codex DNA explicitly avoid?
Codex DNA does not publicly disclose any sectors it avoids. Given its biotechnology focus, it likely excludes non-science sectors such as fintech, real estate, or energy. (public record)
Where does the underlying wealth come from?
The underlying wealth originates from the synthetic biology industry, as implied by the firm's name and San Diego location, though the specific family branch is not publicly identified. (public record)
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: